Key result
Individualized perioperative hemodynamic goal-directed therapy is being investigated in the iPEGASUS trial to determine if it reduces the 28-day composite of moderate or severe complications or death.
Why the study?
Does perioperative individualized hemodynamic goal-directed therapy reduce moderate or severe postoperative complications or death in patients undergoing major abdominal surgery?
Population
380 patients undergoing major abdominal surgery including visceral, urological, and gynecological operations
Comparison
Perioperative, algorithm-driven, hemodynamic… vs Standard local care based on established basic…
Design
Randomly allocated to two treatment arms
Follow-up
6 months
Authors
Loading...
Does not yet support routine individualized perioperative hemodynamic therapy; iPEGASUS trial leaves open effect on 28-day complications.
RCT (n=380)
Single-blind (outcome assessors)
Block randomization (blocks of 6)
Yes
Does perioperative individualized hemodynamic goal-directed therapy reduce moderate or severe postoperative complications or death in patients undergoing major abdominal surgery?
This study protocol outlines a randomized trial to determine if individualized perioperative hemodynamic goal-directed therapy reduces complications and mortality in major abdominal surgery.
Funcke et al. (2018) conducted an RCT in Major abdominal surgery (n=380). Individualized, perioperative, hemodynamic goal-directed therapy vs. Standard local care was evaluated on Composite of moderate or severe postoperative complications or death within 28 days post surgery. Individualized perioperative hemodynamic goal-directed therapy is being investigated in the iPEGASUS trial to determine if it reduces the 28-day composite of moderate or severe complications or death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: